Dynavax Technologies Corp
NASDAQ:DVAX

Watchlist Manager
Dynavax Technologies Corp Logo
Dynavax Technologies Corp
NASDAQ:DVAX
Watchlist
Price: 12.42 USD 0.49% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Dynavax Technologies Corp?
Write Note

Dynavax Technologies Corp
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dynavax Technologies Corp
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Dynavax Technologies Corp
NASDAQ:DVAX
Total Equity
$681.4m
CAGR 3-Years
116%
CAGR 5-Years
77%
CAGR 10-Years
19%
Abbvie Inc
NYSE:ABBV
Total Equity
$6B
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Total Equity
$18.4B
CAGR 3-Years
-5%
CAGR 5-Years
-2%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Total Equity
$7.5B
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
-11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Equity
$15.6B
CAGR 3-Years
18%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Equity
$29.3B
CAGR 3-Years
19%
CAGR 5-Years
23%
CAGR 10-Years
28%
No Stocks Found

Dynavax Technologies Corp
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 311 full-time employees. The company went IPO on 2004-02-19. The firm's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The firm also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The firm is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). The company is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.

DVAX Intrinsic Value
7.57 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Dynavax Technologies Corp's Total Equity?
Total Equity
681.4m USD

Based on the financial report for Sep 30, 2024, Dynavax Technologies Corp's Total Equity amounts to 681.4m USD.

What is Dynavax Technologies Corp's Total Equity growth rate?
Total Equity CAGR 10Y
19%

Over the last year, the Total Equity growth was 13%. The average annual Total Equity growth rates for Dynavax Technologies Corp have been 116% over the past three years , 77% over the past five years , and 19% over the past ten years .

Back to Top